Preclinical evaluation of NETA-based bifunctional ligand for radioimmunotherapy applications using 212Bi and 213Bi: radiolabeling, serum stability, and biodistribution and tumor uptake studies.

[1]  Hyun A. Song,et al.  Synthesis and preclinical evaluation of bifunctional ligands for improved chelation chemistry of 90Y and 177Lu for targeted radioimmunotherapy. , 2012, Bioconjugate chemistry.

[2]  M. Brechbiel,et al.  Synthesis and evaluation of a bifunctional chelate for development of Bi(III)-labeled radioimmunoconjugates. , 2011, Bioorganic & medicinal chemistry letters.

[3]  M. Brechbiel,et al.  Efficient bifunctional decadentate ligand 3p-C-DEPA for targeted α-radioimmunotherapy applications. , 2011, Bioconjugate chemistry.

[4]  Xiang Ma,et al.  Efficient synthesis and evaluation of bimodal ligand NETA. , 2008, Bioorganic & medicinal chemistry letters.

[5]  K. Schwarz,et al.  Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells. , 2007, Cancer research.

[6]  S. Kneifel,et al.  Local Targeting of Malignant Gliomas by the Diffusible Peptidic Vector 1,4,7,10-Tetraazacyclododecane-1-Glutaric Acid-4,7,10-Triacetic Acid-Substance P , 2006, Clinical Cancer Research.

[7]  M. Brechbiel,et al.  In vitro and in vivo evaluation of novel ligands for radioimmunotherapy. , 2006, Nuclear medicine and biology.

[8]  Yong Li,et al.  Intralesional targeted alpha therapy for metastatic melanoma , 2005, Cancer biology & therapy.

[9]  M. Brechbiel,et al.  Targeting of HER2 Antigen for the Treatment of Disseminated Peritoneal Disease , 2004, Clinical Cancer Research.

[10]  M. Brechbiel,et al.  Development of a spectroscopic assay for bifunctional ligand-protein conjugates based on copper. , 2004, Nuclear medicine and biology.

[11]  M. Brechbiel,et al.  Antibody-targeted radiation cancer therapy , 2004, Nature Reviews Drug Discovery.

[12]  L. Chappell,et al.  Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid for radiolabeling proteins. , 2003, Nuclear medicine and biology.

[13]  J. Humm,et al.  Targeted α particle immunotherapy for myeloid leukemia , 2002 .

[14]  M. Brechbiel,et al.  Synthesis and biological evaluation of novel macrocyclic ligands with pendent donor groups as potential yttrium chelators for radioimmunotherapy with improved complex formation kinetics. , 2002, Journal of medicinal chemistry.

[15]  L. Chappell,et al.  In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. , 2002, Nuclear medicine and biology.

[16]  M. Brechbiel,et al.  The Development of the α‐Particle Emitting Radionuclides 212Bi and 213Bi, and Their Decay Chain Related Radionuclides, for Therapeutic Applications , 2001 .

[17]  M. Brechbiel,et al.  The development of the alpha-particle emitting radionuclides 212Bi and 213Bi, and their decay chain related radionuclides, for therapeutic applications. , 2001, Chemical reviews.

[18]  S. Mirzadeh,et al.  In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates. , 2001, Cancer biotherapy & radiopharmaceuticals.

[19]  R. Dillman,et al.  Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: a benefit-risk update. , 2000, Seminars in oncology.

[20]  P. Bunn,et al.  HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. , 2000, Seminars in oncology.

[21]  Y. Erdi,et al.  Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  D. Scheinberg,et al.  Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  R. Finn,et al.  Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs , 1998, Oncogene.

[24]  Krishan Kumar,et al.  Lead(II) and bismuth(III) complexes of the polyazacycloalkane-N-acetic acids nota, dota, and teta , 1989 .